Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

专注于制药的生物科技公司Edgewise Therapeutics, Inc.宣布，自2025年1月8日起，将Behrad Derakhshan博士晋升为首席运营官。这家总部位于博尔德的公司在纳斯达克上市，股票代码为NASDAQ:EWTX，最近在向美国证券交易委员会（SEC）提交的文件中披露了这一高管变动。

周五，JPMorgan分析师将Edgewise Therapeutics (NASDAQ: EWTX )的目标价从$44.00上调至$45.00。该股继续保持"增持"评级，显示出分析师对公司前景的信心。根据InvestingPro数据显示，该公司保持稳健的财务状况，现金多于债务，流动比率高达26.35倍，不过目前的市场价格显示该股可能高于其公允价值。

Edgewise Therapeutics (NASDAQ:EWTX) received an updated price target from JPMorgan, with analysts at the firm raising their ...

JPMorgan analyst Tessa Romero placed shares of Edgewise Therapeutics (EWTX) on “Positive Catalyst Watch” while keeping an Overweight rating on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against Andreas Halvorsen’s other long-term stock picks. Andreas Halvorsen is a prominent ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Edgewise Therapeutics , Inc. (NASDAQ:EWTX), with a market capitalization of $2.67 billion, is a biopharmaceutical company focused on developing innovative therapies for severe, rare muscle disorders.